TREM2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages

TREM2, a myeloid cell-specific signaling molecule, controls essential functions of microglia and impacts on the pathogenesis of Alzheimer’s disease and other neurodegenerative disorders. TREM2 is also highly expressed in tumor-associated macrophages and plays detrimental roles in an experimental mouse sarcoma model. Here we studied whether TREM2 influences glioma progression. We found a sex- dependent effect of TREM2: the glioma volume is significantly attenuated in TREM2- deficient male but not female mice injected with GL261-EGFP glioma cells. The accumulation of glioma-associated microglia/macrophages (GAMs) and vascularization is reduced in male TREM2-deficient mice. A transcriptomic analysis of glioma tissue revealed that TREM2 deficiency suppresses angiogenic genes and MHC clusters. In an organotypic slice model devoid of functional vascularization, the tumor size was not affected by TREM2-deficiency. In human resection samples from glioblastoma, TREM2 is upregulated in GAMs. Based on the TCGA and CGGA databases, the TREM2 expression levels are negatively correlated with survival. Thus, the TREM2-dependent crosstalk between GAMs and the vasculature formation promotes glioma growth. Graphic abstract TREM2-dependent crosstalk between glioma-associated microglia/macrophages and the vasculature formation promotes glioma growth in male glioma mouse model. Created with BioRender.com

[1]  Timothy A. Miller,et al.  TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma , 2023, Science advances.

[2]  H. Kettenmann,et al.  Sex-specific microglia state in the Neuroligin-4 knock-out mouse model of autism spectrum disorder , 2023, Brain, Behavior, and Immunity.

[3]  I. Mellinghoff,et al.  Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. , 2023, JAMA.

[4]  Bing Tao,et al.  Worldwide productivity and research trend of publications concerning glioma-associated macrophage/microglia: A bibliometric study , 2022, Frontiers in Neurology.

[5]  L. Qi,et al.  Worldwide Productivity and Research Trend of Publications Concerning Cancer-Related Neuropathic Pain: A Bibliometric Study , 2022, Journal of pain research.

[6]  Maohui Luo,et al.  A map of the spatial distribution and tumour‐associated macrophage states in glioblastoma and grade 4 IDH‐mutant astrocytoma , 2022, The Journal of pathology.

[7]  A. Madi,et al.  MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors , 2022, bioRxiv.

[8]  Eunjin Lim,et al.  ICAM-1 promotes cancer progression by regulating SRC activity as an adapter protein in colorectal cancer , 2022, Cell Death & Disease.

[9]  Su-Jae Lee,et al.  Correction: ICAM-1 promotes cancer progression by regulating SRC activity as an adapter protein in colorectal cancer , 2022, Cell Death & Disease.

[10]  Yu Wang,et al.  ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer , 2022, Frontiers in Cell and Developmental Biology.

[11]  Dingguo Zhang,et al.  Runx1 regulates Tff1 expression to expedite viability of retinal microvascular endothelial cells in mice with diabetic retinopathy. , 2022, Experimental eye research.

[12]  M. Mattson,et al.  TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration , 2021, Nature Neuroscience.

[13]  N. Jahchan,et al.  Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. , 2021, Cell reports.

[14]  H. Daldrup-Link,et al.  Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance. , 2021, Pharmacological research.

[15]  D. Gutmann,et al.  RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. , 2021, Neuro-oncology.

[16]  U. Knippschild,et al.  Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells , 2021, Pharmaceuticals.

[17]  M. Mattson,et al.  TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration , 2021, bioRxiv.

[18]  Jacob S. Young,et al.  Mouse models of glioblastoma for the evaluation of novel therapeutic strategies , 2021, Neuro-oncology advances.

[19]  Leland S. Hu,et al.  Sex differences in health and disease: A review of biological sex differences relevant to cancer with a spotlight on glioma. , 2020, Cancer letters.

[20]  C. Haass,et al.  Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease , 2020, Neuron.

[21]  Maxim N. Artyomov,et al.  TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy , 2020, Cell.

[22]  I. Amit,et al.  Coupled scRNA-Seq and Intracellular Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer , 2020, Cell.

[23]  H. Kettenmann,et al.  Synergistic Toll-like Receptor 3/9 Signaling Affects Properties and Impairs Glioma-Promoting Activity of Microglia , 2020, The Journal of Neuroscience.

[24]  H. Rhinn,et al.  Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model , 2020, The Journal of experimental medicine.

[25]  A. Heimberger,et al.  Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment , 2020, The EMBO journal.

[26]  M. McCarthy,et al.  Microglia and sexual differentiation of the developing brain: A focus on extrinsic factors , 2020, Glia.

[27]  C. Brennan,et al.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells , 2020, Cell.

[28]  M. Simons,et al.  Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region , 2020, EMBO molecular medicine.

[29]  S. Tsao,et al.  Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF‐1α‐independent VEGF expression and angiogenesis in hepatocellular carcinoma , 2020, British journal of pharmacology.

[30]  Z. Wang,et al.  Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients , 2020, bioRxiv.

[31]  H. Kettenmann,et al.  Microglia/Brain Macrophages as Central Drivers of Brain Tumor Pathobiology , 2019, Neuron.

[32]  R. Tanzi,et al.  TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer’s Disease , 2019, Neuron.

[33]  Christopher M. Jackson,et al.  Mechanisms of immunotherapy resistance: lessons from glioblastoma , 2019, Nature Immunology.

[34]  Shelly C. Lu,et al.  Hyaluronan synthase 2–mediated hyaluronan production mediates Notch1 activation and liver fibrosis , 2019, Science Translational Medicine.

[35]  B. Guleng,et al.  miR-632 promotes gastric cancer progression by accelerating angiogenesis in a TFF1-dependent manner , 2019, BMC Cancer.

[36]  N. Warrington,et al.  Sex differences in GBM revealed by analysis of patient imaging, transcriptome, and survival data , 2019, Science Translational Medicine.

[37]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[38]  W. Wurst,et al.  The Trem2 R47H Alzheimer’s risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans , 2018, Molecular Neurodegeneration.

[39]  D. Beule,et al.  Transcriptional and Translational Differences of Microglia from Male and Female Brains. , 2018, Cell reports.

[40]  C. Bettegowda,et al.  Current state of immunotherapy for glioblastoma , 2018, Nature Reviews Clinical Oncology.

[41]  M. McCarthy,et al.  Microglia: Driving critical periods and sexual differentiation of the brain , 2018, Developmental neurobiology.

[42]  Jill S Barnholtz-Sloan,et al.  Females have the survival advantage in glioblastoma. , 2018, Neuro-oncology.

[43]  Steffen Dettling,et al.  When Immune Cells Turn Bad—Tumor-Associated Microglia/Macrophages in Glioma , 2018, International journal of molecular sciences.

[44]  P. Vajkoczy,et al.  VEGF as a modulator of the innate immune response in glioblastoma , 2018, Glia.

[45]  W. Wurst,et al.  The FTD‐like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism , 2017, The EMBO journal.

[46]  W. Wurst,et al.  TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury , 2017, EMBO reports.

[47]  D. Gutmann,et al.  Ccl5 establishes an autocrine high-grade glioma growth regulatory circuit critical for mesenchymal glioblastoma survival , 2017, Oncotarget.

[48]  M. Davis.  Glioblastoma: Overview of Disease and Treatment. , 2016, Clinical journal of oncology nursing.

[49]  I. Knuesel,et al.  TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance , 2016, EMBO molecular medicine.

[50]  K. Plate,et al.  Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model. , 2016, Neuro-oncology.

[51]  M. Prados,et al.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. , 2016, Neuro-oncology.

[52]  F. Heppner,et al.  Resident microglia rather than peripheral macrophages promote vascularization in brain tumors and are source of alternative pro-angiogenic factors , 2016, Acta Neuropathologica.

[53]  Helmut Kettenmann,et al.  The role of microglia and macrophages in glioma maintenance and progression , 2015, Nature Neuroscience.

[54]  Y. Wang,et al.  Critical roles of chemokine receptor CCR5 in regulating glioblastoma proliferation and invasion. , 2015, Acta biochimica et biophysica Sinica.

[55]  F. Heppner,et al.  Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. , 2015, Neuro-oncology.

[56]  Pierre Robe,et al.  Changing incidence and improved survival of gliomas. , 2014, European journal of cancer.

[57]  J. Molinuevo,et al.  TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis , 2014, Science Translational Medicine.

[58]  A. Sutton,et al.  Angiogenic properties of the chemokine RANTES/CCL5. , 2011, Biochemical Society transactions.

[59]  H. Kettenmann,et al.  The brain tumor microenvironment , 2011, Glia.

[60]  P. Carmeliet,et al.  Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. , 2011, Current opinion in genetics & development.

[61]  W. Seaman,et al.  A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia , 2009, Journal of Neurochemistry.

[62]  L. Reynolds,et al.  Integrins: the keys to unlocking angiogenesis. , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[63]  L. Piccio,et al.  Cutting Edge: TREM-2 Attenuates Macrophage Activation1 , 2006, The Journal of Immunology.

[64]  D. Zagzag,et al.  Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.

[65]  M. Colonna.  TREMs in the immune system and beyond , 2003, Nature Reviews Immunology.

[66]  R. Verhaak,et al.  GlioVis data portal for visualization and analysis of brain tumor expression datasets. , 2017, Neuro-oncology.

[67]  Hui-Lung Sun,et al.  CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. , 2015, Carcinogenesis.

[68]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.